Lynwood Capital Management Inc. Bria Cell Therapeutics Corp. Transaction History

Lynwood Capital Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 01, 2023	SELL	$5.42 - $7.53 $7,739 - $10,752	-1,428 Reduced 0.09%	1,582,450 $9.89 Million
Q2 2023 Aug 14, 2023	BUY	$5.72 - $7.58 $308,182 - $408,395	53,878 Added 3.52%	1,583,878 $10.2 Million
Q4 2022 Feb 07, 2023	BUY	$4.28 - $6.73 $1.42 Million - $2.23 Million	332,000 Added 27.71%	1,530,000 $6.69 Million
Q3 2022 Oct 25, 2022	BUY	$3.0 - $8.31 $1.75 Million - $4.84 Million	583,000 Added 94.8%	1,198,000 $6.73 Million
Q2 2022 Aug 02, 2022	SELL	$4.28 - $11.9 $577,800 - $1.61 Million	-135,000 Reduced 18.0%	615,000 $3.55 Million
Q1 2022 May 05, 2022	SELL	$5.91 - $10.14 $206,850 - $354,900	-35,000 Reduced 4.46%	750,000 $7.61 Million
Q4 2021 Feb 11, 2022	BUY	$7.1 - $10.61 $5.57 Million - $8.33 Million	785,000 New	785,000 $6.5 Million

Ticker BCTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,518,000
Market Cap $8.38M
Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...

Get notified when there are updates to the investment portfolio of Lynwood Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Lynwood Capital Management Inc. with notifications on news.